CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) Form S-1 — Jun 25, 2026
Creative Medical Technology Holdings filed an S-1 registration statement for a best-efforts public offering of up to 3,045,685 shares of common stock and accompanying warrants. The company estimates net proceeds of approximately $5.34 million based on an assumed offering price of $1.97 per share, which will be used to fund Phase I/II clinical trials for chronic lower back pain and Type I Diabetes. Roth Capital Partners is acting as the exclusive placement agent on a best-efforts basis with an 8% cash commission. The offering includes warrants to purchase 6,091,371 shares of common stock exercisable immediately, with officers and directors subject to a 90-day lock-up period.
Key figures
- Offering Price
- 1.97
- Shares Offered
- 3045685
- Estimated Net Proceeds
- 5340000
- Pre Funded Warrants Max
- 3045685
- Public Warrants Offered
- 6091371
- Placement Agent Fee Percent
- 8
- Immediate Dilution Per Share
- 0.37
Price after filing
Close on the filing date to close N calendar days later (from $2.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.